IVBXF Quote, Financials, Valuation and Earnings

CASI Pharmaceuticals has a net margin of -- compared to Innovent Biologics's net margin of -172.28%. Innovent Biologics's return on equity of -0.75% beat CASI Pharmaceuticals's return on equity of -630.22%.

Innovent Biologics has a consensus price target of --, signalling downside risk potential of --. On the other hand CASI Pharmaceuticals has an analysts' consensus of $4.00 which suggests that it could grow by 111.64%. Given that CASI Pharmaceuticals has higher upside potential than Innovent Biologics, analysts believe CASI Pharmaceuticals is more attractive than Innovent Biologics.

Innovent Biologics has a beta of -0.284, which suggesting that the stock is 128.353% less volatile than S&P 500. In comparison CASI Pharmaceuticals has a beta of 0.764, suggesting its less volatile than the S&P 500 by 23.625%.

Innovent Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CASI Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innovent Biologics pays -- of its earnings as a dividend. CASI Pharmaceuticals pays out -- of its earnings as a dividend.

Innovent Biologics quarterly revenues are --, which are smaller than CASI Pharmaceuticals quarterly revenues of $6.2M. Innovent Biologics's net income of -- is lower than CASI Pharmaceuticals's net income of -$10.8M. Notably, Innovent Biologics's price-to-earnings ratio is -- while CASI Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovent Biologics is 9.70x versus 0.96x for CASI Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

China Pharma Holding has a net margin of -- compared to Innovent Biologics's net margin of -69.14%. Innovent Biologics's return on equity of -0.75% beat China Pharma Holding's return on equity of -61.79%.

Innovent Biologics has a consensus price target of --, signalling downside risk potential of --. On the other hand China Pharma Holding has an analysts' consensus of -- which suggests that it could fall by --. Given that Innovent Biologics has higher upside potential than China Pharma Holding, analysts believe Innovent Biologics is more attractive than China Pharma Holding.

Innovent Biologics has a beta of -0.284, which suggesting that the stock is 128.353% less volatile than S&P 500. In comparison China Pharma Holding has a beta of 0.854, suggesting its less volatile than the S&P 500 by 14.629%.

Innovent Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. China Pharma Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innovent Biologics pays -- of its earnings as a dividend. China Pharma Holding pays out -- of its earnings as a dividend.

Innovent Biologics quarterly revenues are --, which are smaller than China Pharma Holding quarterly revenues of $1.1M. Innovent Biologics's net income of -- is lower than China Pharma Holding's net income of -$785.6K. Notably, Innovent Biologics's price-to-earnings ratio is -- while China Pharma Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovent Biologics is 9.70x versus 0.83x for China Pharma Holding. Usually stocks with elevated PS ratios are considered overvalued.

Sinovac Biotech has a net margin of -- compared to Innovent Biologics's net margin of --. Innovent Biologics's return on equity of -0.75% beat Sinovac Biotech's return on equity of -1.05%.

Innovent Biologics has a consensus price target of --, signalling downside risk potential of --. On the other hand Sinovac Biotech has an analysts' consensus of -- which suggests that it could fall by --. Given that Innovent Biologics has higher upside potential than Sinovac Biotech, analysts believe Innovent Biologics is more attractive than Sinovac Biotech.

Innovent Biologics has a beta of -0.284, which suggesting that the stock is 128.353% less volatile than S&P 500. In comparison Sinovac Biotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Innovent Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. Innovent Biologics pays -- of its earnings as a dividend. Sinovac Biotech pays out -328.35% of its earnings as a dividend.

Innovent Biologics quarterly revenues are --, which are smaller than Sinovac Biotech quarterly revenues of --. Innovent Biologics's net income of -- is lower than Sinovac Biotech's net income of --. Notably, Innovent Biologics's price-to-earnings ratio is -- while Sinovac Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovent Biologics is 9.70x versus 1.49x for Sinovac Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Zai Lab has a net margin of -- compared to Innovent Biologics's net margin of -45.49%. Innovent Biologics's return on equity of -0.75% beat Zai Lab's return on equity of -33.29%.

Innovent Biologics has a consensus price target of --, signalling downside risk potential of --. On the other hand Zai Lab has an analysts' consensus of $55.34 which suggests that it could grow by 83.61%. Given that Zai Lab has higher upside potential than Innovent Biologics, analysts believe Zai Lab is more attractive than Innovent Biologics.

Innovent Biologics has a beta of -0.284, which suggesting that the stock is 128.353% less volatile than S&P 500. In comparison Zai Lab has a beta of 1.037, suggesting its more volatile than the S&P 500 by 3.742%.

Innovent Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innovent Biologics pays -- of its earnings as a dividend. Zai Lab pays out -- of its earnings as a dividend.

Innovent Biologics quarterly revenues are --, which are smaller than Zai Lab quarterly revenues of $106.5M. Innovent Biologics's net income of -- is lower than Zai Lab's net income of -$48.4M. Notably, Innovent Biologics's price-to-earnings ratio is -- while Zai Lab's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovent Biologics is 9.70x versus 7.32x for Zai Lab. Usually stocks with elevated PS ratios are considered overvalued.